Skip to content

Effect of Chamomile tea consumption in the treatment of patients with Type 2 diabetes

Effect of Chamomile tea consumption on metabolic status, oxidative stress and inflammation in Type 2 diabetic patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013012712299N1
Enrollment
64
Registered
2013-04-05
Start date
2013-04-09
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group will receive daily 3 cups of Chamomile tea immediately after the meal for 8 weeks( each cup of Chamomile tea is produced by putting Chamomile tea bag contains 3 gra
Treatment - Drugs
Intervention group will receive daily 3 cups of Chamomile tea immediately after the meal for 8 weeks( each cup of Chamomile tea is produced by putting Chamomile tea bag contains 3 grams in 150 cc of
control group 3 cups lukewarm boiled water daily over the same period (per cup after meal consumption)

Sponsors

Nutritional Research Center of Tabriz University of Medical Sciences
Lead Sponsor
Vice chancellor for Research, Tabriz University of Medical Sciences
Collaborator

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Type 2 diabetes for at least 6 months, age between 30-60 years, usage of blood glucose lowering drugs Exclusion criteria: usage of nutritional supplements in the past 3 months or during the study, usage of insulin, Pregnancy or lactation, BMI more than 37, Renal failure, liver disease, Cardiovascular disease, thyroid disorders, History of allergy, smoking, alcohol usage, Following a specific diet, Taking corticosteroids or immunosuppressive drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fasting blood glucose. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: Enzymatic colorimetric.;Fasting insulin serum. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: ELISA assay.;HbA1C (Glycosilated hemoglobin). Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: ELISA.;Insulin resistance. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: HOMA-IR calculation.;Lipid profiles (TC, TG, LDL-C, HDL-C). Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: Enzymatic methods for TC,TG and HDL-C For LDL-C : Freidwald’s formula: LDL-C = TC- HDL-C - (TG/5).;Serum malondialdehyde(MDA). Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: spectrophotometry.;Serum total antioxidant capacity. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: spectrophotometry.;GPX activity. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: spectrophotometry.;SOD activity. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: spectrophotometry.;Catalase enzyme activity. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: spectrophotometry.;Hc-CRP. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: immunoturbidimetry.;TNF-a. Timepoint: Baseline and after 8 weeks of intervention. Method of measurement: ELISA.

Secondary

MeasureTime frame
Macronutrients intake. Timepoint: before and after 8 weeks intervention. Method of measurement: 24-h recall Questionnaire.;Anthropometric index(weight and Body Mass Index). Timepoint: before and after 8 weeks intervention. Method of measurement: Analogue scale for weight and weight(Kg)/Square Height for body mass index.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Zemestani

Tabriz University of Medical Sciences

maryam.zemestani@yahoo.com+98 41 1335 2295

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026